SynBalance SRL is proud to announce that Health Canada has officially authorized the functional claim for SynbÆctive® Femme, a patented probiotic combination featuring L. plantarum PBS068, L. rhamnosus LRH020, and B. lactis BL050, specifically focused on women’s urogenital health.
Taking care of women’s urogenital health is crucial, as it plays a key role in preventing infections like bacterial vaginosis, which affects up to 30% of women. Prioritizing urogenital health can enhance overall well-being, reduce the risk of chronic conditions, and support long-term health, enabling women to lead more active, comfortable, and fulfilling lives.
Femme has been extensively studied, with three clinical studies confirming its efficacy in improving urogenital health. The first study demonstrated Femme’s strains successfully colonized and persisted in the vaginal environment, migrating from the intestinal tract. A second study showed Femme significantly reduced bacterial vaginosis recurrence and promoted a healthy vaginal microbiota. In menopausal women, after 28 days, Femme exhibited strong anti-inflammatory effects, increased lactobacilli, and improved vaginal health.
With the authorization from Health Canada, SynBalance strengthens its credibility and visibility in the North American market, promoting closer relationships with local partners and customers.
Femme strains have been authorized for the following urogenital claims:
- Helps support feminine and digestive health
- Helps naturally maintain/support feminine health
- Clinically shown to help support vaginal health
- Helps maintain healthy vaginal flora
“We are thrilled that an institution as rigorous as Health Canada has recognized the quality and scientific value of Femme,” said Cristiana Piangiolino, Managing Director of SynBalance SRL. “This achievement reflects our dedication to developing innovative, science-backed probiotic ingredients. We also want to extend our gratitude to our Canadian partner Prebionature for their invaluable support throughout this journey. We are looking forward to seeing the first Canadian-licensed formulations in market in early 2025.”
With this important milestone, SynbÆctive® Femme is set to become a trusted solution for women’s health across Canada.
About SynBalance Srl
SynBalance develops and studies proprietary probiotic strains belonging to Lactobacilli and Bifidobacteria as ingredients, combined as branded or customized formulations, or available as white label products too. Its mission is to provide clinically proven probiotics, their derivatives and other microbiome-related technologies, taking care of people’s health through prevention of chronic disease and aging. SynBalance portfolio is designed to target various health functions such women’s health, gut-skin axis, mental health, cardiovascular prevention, and immune system through a respectful and sustainable modulation of the intestinal microbiota. SynBalance versatile business model allows supporting customers with particular attention to efficacy, competitiveness and time-to-market.
Content sponsored by Synbalance
More information on: https://www.synbalance.care
LinkedIn: https://www.linkedin.com/company/synbalance-probiotics/
Instagram: https://www.instagram.com/synbalance_probiotics/
Facebook: https://www.facebook.com/SynBalance
